lumacaftor ivacaftor
Selected indexed studies
- Lumacaftor/ivacaftor for cystic fibrosis. (Aust Prescr, 2019) [PMID:31631933]
- ** (, 2024) [PMID:39965067]
- The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis. (Expert Opin Drug Saf, 2017) [PMID:28846049]
_Worker-drafted node — pending editorial review._
Connections
lumacaftor ivacaftor is a side effect of
Sources
- Ivacaftor-tezacaftor-elexacaftor, tezacaftor-ivacaftor and lumacaftor-ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation. (2025) pubmed
- PMID:39965067 (2024) pubmed
- Lumacaftor/ivacaftor for cystic fibrosis. (2019) pubmed
- The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis. (2017) pubmed
- Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis. (2016) pubmed
- Lumacaftor and Ivacaftor. (2006) pubmed
- Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy. (2019) pubmed
- Pharmacokinetics of Ivacaftor, Tezacaftor, Elexacaftor, and Lumacaftor in Special Cystic Fibrosis Populations: A Systematic Review. (2025) pubmed
- Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR. (2016) pubmed
- In utero and postnatal ivacaftor/lumacaftor therapy rescues multiorgan disease in CFTR-F508del ferrets. (2024) pubmed